deltatrials
Unknown PHASE2 NCT02366325

Safety & Efficacy of EPO-018B for the Treatment of Anemia in Participants With ERSD Receiving Maintenance Hemodialysis

A Phase 2, Open-Label, Multi-Center , Dose-Finding Study of the Safety and Efficacy of Pegol-Sihematide (EPO-018B) for the Treatment of Anemia in Patients With End-Stage Renal Disease Receiving Maintenance Hemodialysis (HD)

Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.

Conditions Anemia Chronic Renal Failure
Interventions EPO-018B
Updated 4 times since 2017 Last updated: Feb 12, 2015 Started: Jul 31, 2014 Primary completion: Dec 31, 2015 Completion: Dec 31, 2015

This PHASE2 trial investigates Anemia and Chronic Renal Failure and is currently ongoing. Jiangsu Hansoh Pharmaceutical Co., Ltd. leads this study, which shows 4 recorded versions since 2014 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

4 versions recorded

  1. Sep 2024 — Present [monthly]

    Unknown PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE2

    Status: Unknown Status → Unknown

  3. Jan 2021 — Jul 2024 [monthly]

    Unknown Status PHASE2

  4. Jan 2017 — Jan 2021 [monthly]

    Unknown Status PHASE2

    First recorded

Jul 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Jiangsu Hansoh Pharmaceutical Co., Ltd.
Data source: Jiangsu Hansoh Pharmaceutical Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Shanghai, China